Roche and Hansoh Sign Broad ADC Licensing Deal Worth Up to $15 Billion
Start here
On October 19, 2026, Hansoh Pharmaceutical announced a strategic collaboration and license agreement with Roche covering a portfolio of antibody-drug conjugate (ADC) programs spanning multiple tumor types. Hansoh will receive a $400 million upfront payment and a $110 million one-year anniversary payment, and is eligible for milestone payments exceeding $15 billion tied to development, regulatory and commercialization progress, plus tiered royalties on future product sales. Under the arrangement, Hansoh leads early development through global Phase 1a trials, while Roche takes on further development outside Greater China, with Hansoh retaining rights in Greater China. The deal mirrors a broader pattern of multinational companies bringing in Chinese drugmakers' R&D through early-stage collaboration, as seen with Hengrui and Bristol Myers Squibb and Innovent with Eli Lilly and Pfizer.
Written by a model from the reports · updated 42 min ago
Coverage timeline
Follow the coverage to see the different angles.
- BioSpacePickRoche returns to Hansoh with broad $15B ADC deal
Roche has signed a licensing agreement with several Hansoh Pharmaceutical subsidiaries for a broad portfolio of ADCs. The deal could total up to $15 billion, including $400 million upfront, $110 million payable at the one-year mark, and the remainder through milestones and tiered sales royalties.
- WeChatHansoh Pharmaceutical and Roche Strike Strategic ADC Collaboration Worth Over $15 Billion
On October 19, 2026, Hansoh Pharmaceutical announced a strategic collaboration and license agreement with Roche covering a portfolio of antibody-drug conjugate (ADC) programs. Under the deal, Hansoh will receive a $400 million upfront payment and a $110 million one-year anniversary payment, plus potential milestone payments exceeding $15 billion tied to development, regulatory and commercialization progress, along with tiered royalties on future product sales.
- WeChatHansoh Pharma and Roche Strike Strategic Licensing Deal for Multi-Tumor ADC Portfolio
Hansoh Pharmaceutical (03692.HK) has entered a strategic collaboration and license agreement with Roche covering an ADC portfolio spanning multiple tumor types. Hansoh is eligible for an upfront payment of 400 million US dollars, a 110-million-dollar one-year anniversary payment, and potential milestone payments exceeding 15 billion dollars, and retains tiered royalties on sales.
- WeChatHansoh Pharmaceutical and Roche Sign ADC Co-Development Deal Worth Over $15 Billion
Hansoh Pharmaceutical and Roche have entered an ADC co-development agreement worth over $15 billion. Hansoh will lead early development through global Phase 1a trials, while Roche will handle further development outside Greater China, with Hansoh retaining rights in Greater China. The deal follows the MNC strategy of systematically bringing in Chinese drugmakers' R&D systems through early-stage collaboration up to initial proof of concept, like Hengrui with Bristol Myers Squibb and Innovent with Eli Lilly and Pfizer.
Coverage and heat for this story
Reports so far 5·Heat now 27·Peak heat 29 (Oct 19 23:00)·Reports, 24h +5
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.